Skip to main content

Table 4 C-reactive protein (CRP) and procalcitonin (PCT) values in patients of acute Q fever with and without delayed responses to doxycycline treatmenta

From: Serum C-reactive protein and procalcitonin values in acute Q fever, scrub typhus, and murine typhus

 Treatment to defervescence ≤3 daysTreatment to defervescence > 3 daysp
CRP (mg/L)
 Acute phase (Mean ± SD) 79.1 ± 61.2107.8 ± 68.80.096
> 2577.6% (52/67)94.1% (16/17)0.174
> 5067.2% (45/67)82.4% (14/17)0.373
> 7544.8% (30/67)58.8% (10/17)0.300
> 10034.3% (23/67)47.1% (8/17)0.331
> 15010.4% (7/67)17.6% (3/17)0.415
> 2003.0% (2/67)11.8% (2/17)0.181
 Convalescent phase (Mean ± SD) b 5.3 ± 17.420.7 ± 45.20.103
> 253.1% (1/32)7.7% (1/13)0.499
> 503.1% (1/32)7.7% (1/13)0.499
> 753.1% (1/32)7.7% (1/13)0.499
> 1000% (0/46)7.1% (1/14)0.289
PCT (ng/mL)
 Acute phase (Mean ± SD) 1.07 ± 1.451.67 ± 1.780.187
> 0.2575.4% (46/61)85.7% (12/14)0.502
> 0.549.2% (30/61)78.6% (11/14)0.073
> 1.029.5% (18/61)57.1% (8/14)0.050*
> 1.523.0% (14/61)28.6% (4/14)0.731
> 2.013.1% (8/61)21.4% (3/14)0.420
> 4.06.6% (4/61)14.3% (2/14)0.311
 Convalescent phase (Mean ± SD)b 0.06 ± 0.100.17 ± 0.200.098
> 0.257.1% (3/42)33.3% (4/12)0.036*
> 0.50% (0/42)8.3% (1/12)0.222
> 1.00% (0/42)0% (0/12)NC
  1. SD standard deviation, NC not calculated
  2. *p < 0.05 indicates statistical significance
  3. aPatients who received fluoroquinolones or achieved defervescence before intervention of doxycycline treatment were excluded
  4. bTests for the convalescent phase of acute Q fever were performed 12–45 days from the disease onset (average, 20.3 ± 6.1 days; median, 18.5 days)